We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+32.65%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.1B
AUM Growth
-$1.29B
Cap. Flow
-$1.61B
Cap. Flow %
-76.67%
Top 10 Hldgs %
43.41%
Holding
94
New
23
Increased
6
Reduced
30
Closed
33

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$63.4M
2
ELV icon
Elevance Health
ELV
+$54.6M
3
CNC icon
Centene
CNC
+$44.4M
4
PFE icon
Pfizer
PFE
+$34.7M
5
ICUI icon
ICU Medical
ICUI
+$28.5M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$121M
2
PEN icon
Penumbra
PEN
+$97.1M
3
ZBH icon
Zimmer Biomet
ZBH
+$77.5M
4
NXPI icon
NXP Semiconductors
NXPI
+$75.2M
5
MCHP icon
Microchip Technology
MCHP
+$72.3M

Sector Composition

Rank Sector Weight
1 Healthcare 69.54%
2 Technology 2.78%
3 Consumer Discretionary 0.53%
4 Financials 0.1%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
1
CALL
Gilead Sciences
GILD
$162B
$197M 9.36%
+3,024,200
New +$197M
ALXN
2
DELISTED
Alexion Pharmaceuticals
ALXN
$116M 5.55%
1,076,442
-370,170
-26% -$39.6M
CI icon
3
CALL
Cigna
CI
$75.4B
$106M 5.06%
+519,500
New +$95.2M
GILD icon
4
Gilead Sciences
GILD
$162B
$87.8M 4.18%
1,351,736
-492,124
-27% -$32M
BOLD
5
DELISTED
Audentes Therapeutics, Inc
BOLD
$73.8M 3.51%
1,232,873
-1,083,065
-47% -$40.6M
PEN icon
6
Penumbra
PEN
$12.4B
$68.8M 3.28%
418,792
-610,772
-59% -$97.1M
NVRO
7
DELISTED
NEVRO CORP.
NVRO
$67.8M 3.23%
577,163
+180,893
+46% +$17.9M
BIIB icon
8
Biogen
BIIB
$29.1B
$67.8M 3.23%
+228,328
New +$63.4M
ZBH icon
9
Zimmer Biomet
ZBH
$17.2B
$66.3M 3.16%
455,906
-561,571
-55% -$77.5M
ELV icon
10
Elevance Health
ELV
$84.4B
$60M 2.86%
+198,548
New +$54.6M
AERI
11
DELISTED
Aerie Pharmaceuticals
AERI
$58.3M 2.78%
2,413,464
+582,540
+32% +$12.1M
CI icon
12
Cigna
CI
$75.4B
$54.3M 2.59%
265,717
-131,967
-33% -$24.2M
AGN
13
DELISTED
Allergan plc
AGN
$53.8M 2.56%
281,548
-174,050
-38% -$31.4M
IQV icon
14
IQVIA
IQV
$33.1B
$53.1M 2.53%
343,567
-133,435
-28% -$19.5M
CNC icon
15
Centene
CNC
$32.5B
$51.5M 2.45%
+819,229
New +$44.4M
ARNA
16
DELISTED
Arena Pharmaceuticals Inc
ARNA
$48.6M 2.32%
1,070,616
-1,200,920
-53% -$56.8M
BMRN icon
17
BioMarin Pharmaceuticals
BMRN
$11.3B
$46.8M 2.23%
553,634
-1,595,417
-74% -$121M
KRTX
18
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$45.4M 2.16%
602,551
+191,908
+47% +$8.41M
HCA icon
19
HCA Healthcare
HCA
$82.5B
$41.3M 1.97%
279,411
-137,322
-33% -$18.4M
NVS icon
20
Novartis
NVS
$292B
$40.7M 1.94%
442,640
-246,960
-36% -$22.2M
PFE icon
21
Pfizer
PFE
$142B
$36.2M 1.72%
+972,975
New +$34.7M
DERM
22
DELISTED
Dermira, Inc.
DERM
$34.4M 1.64%
2,271,180
-1,558,356
-41% -$13.5M
ICLR icon
23
Icon
ICLR
$12.9B
$33.3M 1.59%
193,577
-43,598
-18% -$6.72M
IMMU
24
DELISTED
Immunomedics Inc
IMMU
$31.7M 1.51%
+1,499,239
New +$26.4M
IRTC icon
25
iRhythm Holdings
IRTC
$3.49B
$31.2M 1.49%
458,241
-622,818
-58% -$42.3M
1
2 3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
CPRC
Consolidated Portfolio Review Corp Woodbury, New York $1.1B AUM 8.96% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return

PFM Health Sciences's Q4 2019 Portfolio in Review

As of Q4 2019, PFM Health Sciences held 94 positions worth $2.1B, down 38% from $3.39B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

PFM Health Sciences withdrew a net $1.61B in Q4 2019, closing 33 positions and reducing 30 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $68.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 60% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, PFM Health Sciences opened a new position in Biogen worth $67.8M.

  • PFM Health Sciences's largest Q4 2019 buy was Biogen: 228,328 shares worth $67.8M.
  • PFM Health Sciences added most to NEVRO CORP. in Q4 2019, an estimated $17.9M increase.
  • PFM Health Sciences's biggest Q4 2019 reduction was BioMarin Pharmaceuticals, cutting an estimated $121M.
  • PFM Health Sciences fully exited Wellcare Health Plans, Inc. in Q4 2019, selling an estimated $68.3M.
  • PFM Health Sciences's ten largest holdings make up 43% of its $2.1B portfolio in Q4 2019.
  • PFM Health Sciences opened 23 new positions and closed 33 in Q4 2019.
  • PFM Health Sciences's portfolio value fell 38% quarter-over-quarter to $2.1B.

Based on PFM Health Sciences's 13F filing for Q4 2019, filed 14 Feb 2020.